
News
from the fight to #SaveIndiePharmacy
New York Times’ The Middlemen series

How PBMs limit access to MS therapies
Pharmacy benefit managers inflate specialty generic prices, restrict pharmacy choice and increase patient costs, leaving many life-saving multiple sclerosis therapies inaccessible.
Drugmakers including Purdue Pharma paid pharmacy benefit managers not to restrict painkiller prescriptions, a New York Times investigation found.